Research and Markets has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2016" report to their offering.
Pulmonary Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 125 molecules are developed by Companies and remaining by the Universities/Institutes.
Pulmonary Fibrosis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Pulmonary Fibrosis Pulmonary fibrosis occurs when lung tissue becomes damaged and scarred. Pulmonary fibrosis can be caused by many conditions, including chronic inflammatory processes (like sarcoidosis or Wegener's granulomatosis), infections, environmental agents (asbestos, silica, exposure to certain gases), and exposure to ionizing radiation. Symptoms include shortness of breath, dry cough, fatigue and aching muscles and joints.
The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 84 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 3 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/2jw43c/pulmonary
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006166/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.